Zealand and Roche Release Phase 2 Data for Petrelintide, Amylin Analogue
FROM THE WIRE · SEEKINGALPHA.COM
Zealand Pharma’s petrelintide Phase 2 cut weight up to 9.2% and improved A1C in type 2 diabetes. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPetrelintide shows positive results in weight reduction and glycemic control in type 2 diabetes.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Petrelintide Phase 2 achieved weight reduction up to 9.2% in type 2 diabetes patients.
- 02The drug also improved A1C, a marker of glycemic control.
- 03Data support the therapeutic potential of the compound for diabetes treatment.